This trial consisted of a 24-week multicentre, randomized, double-blind, double-dummy, active-controlled study and a 52-week open label extension study to assess the efficacy and safety of evogliptin, a novel dipeptidyl peptidase-4 inhibitor, compared to sitagliptin in patients with type 2 diabetes who have inadequate glycaemic control with metformin alone.
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| INTRODUCTION
Dipeptidyl peptidase 4 (DPP-4) inhibitors comprise a relatively novel pharmacological class of glucose-lowering agents that inhibit the degradation of glucagon-like peptide 1 (GLP-1) and cause modest elevations in circulating GLP-1 levels. They do not cause hypoglycaemia unless used in combination with sulfonylureas or insulin and they also do not cause weight gain. 1 Therefore, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have published consensus guidelines for pharmacotherapy to control hyperglycaemia in type 2 diabetes, recommending DPP-4 inhibitors as second-or first-line agents in specific situations. Likewise, the American
Association of Clinical Endocrinologists and the American College of
Endocrinology have published a consensus statement recommending DPP-4 inhibitors as an acceptable alternative to metformin as initial therapy. 2, 3 Moreover, DPP-4 inhibitors are currently widely used as second line treatment for patients with type 2 diabetes (T2DM). 4 Evogliptin is a novel antidiabetic agent that potently and selectively inhibits DPP-4. Namyi Gu et al. reported the pharmacokinetic and pharmacodynamic profiles of evogliptin in healthy subjects. 5 The peak plasma concentration of evogliptin was reached within 4 to 5 hours. The inhibition of DPP-4 activity (>80%) was sustained for over 24 hours, and it provided an increase in postprandial active GLP-1 levels, 1.5-to 2.4-fold. As a result, evogliptin reduced postprandial glucose by 20% to 35% compared to placebo. 5 And another study reported the pharmacokinetic and pharmacodynamic profiles of evogliptin in renal impairment; the plasma concentration of evogliptin increased 1.98 times in severe renal impairment, but within a therapeutic window. 6 Drug administration in patients with T2DM is usually performed over extended periods of time; therefore, an evaluation of the safety and efficacy of these drugs over a long term is extremely important. However, there was no more than 12 weeks of follow-up for the study with evogliptin. Therefore, we conducted this phase III, randomized, double-blind, active-controlled, parallel-group, multicentre study to determine the efficacy and safety of evogliptin compared to sitagliptin for 24 weeks in Korean patients with T2DM, and we also determined the efficacy and safety of evogliptin over an extension period of 52 weeks.
| METHODS
This study consisted of a randomized, double-blind, active-controlled, parallel-group, multi-centre, dose-confirmatory study. The study was conducted at 24 university hospitals throughout Korea between May 2013 and November 2014 (ClinicalTrials.gov Identifier: NCT02949193).
The study was conducted in accordance with the principles of Good Clinical Practice, and it was approved by the appropriate institutional review boards and regulatory agencies. All patients provided written informed consent prior to participation.
| Participants
Participants eligible for the study were patients aged 18 years and older with T2DM who recently had experienced inadequate glycaemic control (6.5% ≤ HbA1c < 11.0%) with metformin monotherapy for more than 12 weeks and metformin ≥ 1000 mg daily for more than 6 weeks. 
| Study design
After a 2-week screening period, eligible and consenting participants underwent baseline evaluation and randomized sampling stratified according to HbA1c (using an 8.5% cut-off ) into 2 parallel groups (evogliptin 5 mg and sitagliptin 100 mg; 1:1 matching). During the 24-week treatment period after randomization, participants visited the investigational site at weeks 6, 12, 18 and 24 ( Figure 1 9 In this study, mean daily glucose (MDG) was derived from the mean value of 7-point glucose measurements (before and 2 hours after breakfast, lunch and dinner, and before bedtime). 
| Study endpoints
The primary efficacy endpoint of this study was change in HbAlc level from baseline to week 24. The secondary efficacy endpoints were change in HbAlc level from baseline to week 52, the HbA1c response rate (HbA1c < 6.5%), rescue therapy rate, changes in FPG, 
| Statistical analysis
The primary objective of the parent study (week 0-24) was to demonstrate the non-inferiority of evogliptin 5 mg once daily vs sitagliptin 100 mg once daily in reducing HbA1c levels from baseline until week 24 (non-inferiority margin δ = 0.35%; if the upper boundary of the 2-sided 95% confidence interval (CI) for the mean difference between evogliptin and sitagliptin was less than the pre-specified non-inferiority margin, evogliptin was assessed as being non-inferior to sitagliptin). A sample size of 104 patients per group was estimated to provide 80% power to prove the non-inferiority between evogliptin and sitagliptin. We assumed an approximate 20% dropout rate (ie, patients who did not complete 24 weeks of treatment). Therefore, a total of 260 patients (in a 1:1 allocation ratio to receive evogliptin 5 mg once daily and sitagliptin 100 mg once daily) were planned to be randomized. Efficacy analyses were based on the full analysis set population, which consisted of all randomized patients who received at least one dose of the study medication and who had a baseline measurement and at least one post-baseline measurement. ANCOVA was used to compare the primary endpoint (change in HbAlc level)
between treatment groups as a sensitivity analysis. In this analysis, stratification factors (site, baseline HbA1c) were set as fixed effects. Table 1 .
Mean age of the study subjects was 57.5 AE 9.3 years, and 103 subjects (46.4%) were men. There were no significant differences in the subjects' baseline characteristics (Table 1) .
| Efficacy
Mean baseline HbA1c values of the evogliptin and sitagliptin groups were 7.42% AE 0.71% and 7.45% AE 0.74%, respectively, and the difference was not statistically significant (P = .9201). Decreases in HbA1c value were observed in the evogliptin and sitagliptin groups until 12 weeks, after which HbA1c values were sustained until 24 weeks (Figure 2 ). Evogliptin and sitagliptin decreased the HbA1c level after treatment during 24 weeks (−0.59% AE 0.61% and −0.65% AE 0.61%, respectively; all P < .0001) ( Table 2 Table 2 ). The upper 95% CI limit (0.22%) was less than the prespecified non-inferiority margin, 0.35%, which confirmed the noninferiority of evogliptin to sitagliptin (Table 2) from the chi-square test) ( Table 2) . Among patients with an HbA1c all P < .0001) levels from baseline through week 24. However, the change in FPG and MDG levels from baseline to week 24 in the 2 medication groups did not show a statistically significant difference (P = .7155 and P = .1062, respectively). After 52 weeks, the evogliptin/ evogliptin group exhibited a persistent decrease in FPG (−0.38 AE 1.19 mmol/L; P = .0048) and MDG (−1.00 AE 1.69 mmol/L; P < .0001).
A subgroup analysis of HbA1c and FPG was carried out for HbA1c levels (≥8.5% or <8.5%), sex (men or women), age (<65 or β-cell function, as assessed by the HOMA-β score, improved in both medication groups at week 24. After 24 weeks, the HOMA-β had increased by 11.36% AE 27.92% (baseline vs week 24; P < .0001) in the evogliptin group and by 11.82% AE 29.43%
(baseline vs week 24; P < .0001) in the sitagliptin group, but the change in the 2 medication groups was not different (P = .3791).
Evogliptin/evogliptin treatment consistently improved β-cell function during 52 weeks (mean change from baseline to week 52, 9.21% AE 26.09%; P = .0026). Unlike HOMA-β, change in fasting insulin, c-peptide, HOMA-IR and QUICKI after 24 weeks was not statistically significant in the evogliptin group (Table S1 , Supporting Information). HOMA-IR and QUICKI showed statistically significant changes in the sitagliptin group (P = .0364 and P = .0094, respectively). Comparing changes from baseline to week 24 between treatment groups, there was no statistically significant difference in HOMA-ß, HOMA-IR and QUICKI.
All fasting lipid parameters, which included total cholesterol, LDL-C, HDL-C, TG and FFA, did not change significantly after 24 weeks of evogliptin treatment nor after 52 weeks of evogliptin/ evogliptin treatment (Table S1 , Supporting Information). The sitagliptin group showed a statistically significant change in FFA from baseline to week 24 (P = .0066) but change in total cholesterol, LDL-C, HDL-C and TG, was not statistically significant in the sitagliptin group. Inter-group comparison of the change from baseline to week 24 revealed that none of the fasting lipid parameters exhibited any statistically significant difference.
After 24 weeks of treatment, mean body weight change from baseline in the evogliptin and sitagliptin groups was −0.14 AE 1.81 kg (P = .4583) and −0.05 AE 1.97 kg (P = .8493), respectively, and it had not changed significantly. After 52 weeks of treatment with evogliptin/evogliptin, body weight change was −0.12 AE 1.90 kg (P = .9691).
| Tolerability and safety
In the parent study, incidences of AE were not significantly different between the 2 groups (P = .4337; chi-square test) ( Table 3) In the parent study, one hypoglycaemic event occurred in 1 case (0.9%) in the evogliptin group and 7 hypoglycaemia events occurred in events with sitagliptin or evogliptin was "probably not" or "definitely not" and the outcome was found to be "recovered without sequelae."
| DISCUSSION
In this phase III, randomized, double-blind, active-controlled study we proved that adding evogliptin or sitagliptin for inadequately con- Pancreatic β-cell dysfunction is one of the primary mechanisms of T2DM pathogenesis. 15 Therefore, the modalities used to improve β-cell function are a critical aspect of T2DM management. In our study, β-cell function was estimated by HOMA-β, and evogliptin improved HOMA-β by 11.36% AE 27.92% (P < .0001) at week 24 and it was not different from the improvement with sitagliptin (11.82% AE 29.43%, P < .0001).
A recent meta-analysis of 27 double-blind, randomized, controlled trials with sitagliptin and saxagliptin, linagliptin, alogliptin showed a similar result; a DPP-4 inhibitor, when added to metformin, increased HOMA-β by 10.21% (95% CI, 7.73-12.69). 16 In a previous clinical study with evogliptin, insulin secretory function, assessed by the insulinogenic index and post-OGTT C-peptide AUC0-2h, was significantly improved at 12 weeks, 10 but the effect of evogliptin on human β-cell function was not clear after 12 weeks. In our study, evogliptin improved HOMA-β (9.21% AE 26.09%, P = .0026) up to week 52. Several studies have suggested that DPP-4 inhibitors increased β-cell mass via increased β-cell neogenesis and decreased β-cell apoptosis in young rodents. [17] [18] [19] Evogliptin treatment in streptozotocin-treated mice increased the volume density of β-cells and the number of replicating β-cells. 20 Evogliptin also
induces Pdx-1 expression in small β-cells, indicating neogenesis, and some insulin-positive islet cells and ductal cells are seen. 20 However, another study reported that vildagliptin treatment in mature rodents failed to increase the β-cell mass. 21 Moreover, in a study in humans, 3-or 12-month treatment periods with vildagliptin or sitagliptin increased the capacity for insulin secretion during treatment, but failed to preserve the increased capacity of insulin secretion after a 2-week drug washout period. [22] [23] [24] Our study showed the possible long-term effects of evogliptin on β-cell function in humans, but additional data with a longer follow-up and drug washout are needed. 25 In the present study, mean changes in HOMA-IR from baseline to 24 weeks showed that evoglipitin did not have a statistically significant effect on insulin resistance (−0.17 AE 1.72, P = .1233). In a previous study among Korean T2DM patients, another DPP-4 inhibitor (vildagliptin) had similar effects when compared to pioglitazone. 26 We first verified the tolerability and safety of a daily dose of evogliptin 5 mg up to week 52. The incidence of AEs was similar to that with use of sitagliptin, which is one of the most widely prescribed DPP-4 inhibitors. The frequency of serious AEs was very low with use of evogliptin and sitagliptin, and both treatment groups showed no serious ADRs. Many conventional glucose-lowering agents commonly result in weight gain, 27 but treatment with evogliptin for 52 weeks resulted in a stable body weight (mean change, −0.12 AE 1.90; P = .9691). Also, the incidence of a hypoglycaemic event during the 24-week period was very low in each treatment group (evogliptin, 0.9% vs sitagliptin, 2.8%), and there was no case of severe hypoglycaemia. In particular, the evogliptin group had only 1 case of asymptomatic hypoglycaemia during the 24-week period.
In conclusion, this study showed that 5 mg of evogliptin exhibits non-inferiority to sitagliptin when added to metformin therapy. This study also showed that adding evogliptin in patients with inadequately controlled T2DM who are being treated with metformin alone is effective in lowering HbA1c and is generally well tolerated and safe until week 52.
